423
Participants
Start Date
October 30, 2019
Primary Completion Date
March 17, 2022
Study Completion Date
March 17, 2022
GV1001 placebo
0.9 % Normal Saline
Proscar placebo
PO
Hanyang University Guri Hospital, Guri-si
Seoul National University Bundang Hospital, Seongnam-si
Dongguk University Gyeongju Hospital, Gyeongju
Hallym University Medical Center, Anyang
Inje University Busan Paik Hospital, Busan
Samsung Changwon Medical Center, Changwon
Soonchunhyang University Hospital, Cheonan
Daegu Catholic University Medical Center, Daegu
Keimyung University Dongsan Medical Center, Daegu
Kyungpook National University Chilgok Hospital, Daegu
Yeungnam University Medical Center, Daegu
Dongguk University Ilsan Hospital, Ilsan
Jeonbuk National University Hospital, Jeonju
Chungbuk National University Hospital, Jungbuk
Chonnam National University Hospital, Jungnam
Asan Medical Center, Seoul
Chung-ang University Hospital, Seoul
Eulji General Hospital, Seoul
Korea University Guro Hospital, Seoul
Samsung Medical Center, Seoul
Severance Hospital, Seoul
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul
Pusan National University Yangsan Hospital, Yangsan
Lead Sponsor
GemVax & Kael
INDUSTRY